MK-0646

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neuroendocrine Tumors

Conditions

Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors

Trial Timeline

Jan 1, 2008 → Jan 1, 2010

NCT ID

NCT00610129

About MK-0646

MK-0646 is a phase 2 stage product being developed by Merck for Neuroendocrine Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00610129. Target conditions include Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors.

What happened to similar drugs?

6 of 16 similar drugs in Neuroendocrine Tumors were approved

Approved (6) Terminated (2) Active (9)

🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

🔄68Ga-DOTATOCJiangsu Hengrui MedicinePhase 3

✅Everolimus (RAD001)NovartisApproved

🔄Everolimus + Everolimus PlaceboNovartisPhase 3

✅Pasireotide + DiazoxideNovartisApproved

🔄[68Ga]Ga-DOTA-TATE + 68Ge/68Ga GeneratorNovartisPhase 3

✅everolimusNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00610129	Phase 2	Completed	Jan 1, 2008	Jan 1, 2010	Neuroendocrine Tumors

Competing Products

20 competing products in Neuroendocrine Tumors

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27
Lenvatinib	Eisai	Phase 2	35
Abemaciclib	Eli Lilly	Phase 2	39
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.	Jiangsu Hengrui Medicine	Phase 3	47
Famitinib	Jiangsu Hengrui Medicine	Phase 2	27
68Ga-DOTATOC	Jiangsu Hengrui Medicine	Phase 3	47
Olaparib	AstraZeneca	Phase 2	27
Avelumab	Merck	Phase 1/2	32
Pembrolizumab	Merck	Phase 2	27
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	35
Pembrolizumab Injection	Merck	Phase 2	27
Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab	Merck	Phase 1	33
Avelumab	Merck	Phase 2	35
Pembrolizumab + Lenvatinib	Merck	Phase 2	35
Avelumab	Merck	Phase 2	35
Pembrolizumab + Irinotecan + Paclitaxel	Merck	Phase 2	35
Lanreotide + Pembrolizumab	Merck	Phase 1/2	32